I began my professional career in the pharmaceutical/health sector in 2002, after graduating from Yıldız Technical University's "Chemical Engineering" department. I worked at Kurtsan as a "Regulatory Affairs Responsible" and subsequently at Kurtsan Medical as a "Product Manager" between 2002-2005. I worked for Sanofi Pasteur outsourced to Manpower, as a "Monitor" for the HAF 65 trial, between 2006-2007, which enabled pursuing my clinical trials career. I ensured that clinical trials were conducted in accordance with international and national standards and ICH-GCP , and I made all essential follow-up and reporting. I worked as a "Clinical Research Associate, CRA" (2007 - 2009) and a "Country Study Manager, CSM" (2009 - 2015) at ROCHE, a global-scale organization that provides solutions in oncology, hematology, virology, dialysis, transplantation, rheumatology, and osteoporosis, between 2007-2015. After the Head of the relevant Department accepted a temporary duty in Egypt, I was chosen from the three CSMs and designated as the "Deputy of Clinical Trials Manager" by proxy.I played a key part in clinical trials and research for various indications such as rheumatoid arthritis, gastric cancer, hepatitis, breast cancer, lymphoma, basal cell carcinoma, dialyzes, during my time in Roche. In my profession, I had the chance to get broad expertise from phase II to IV clinical trials and also post-authorisation studies including planning and publishing. By anticipating difficulties that emerged/may arise in the procedures, I was able to promptly remedy them. I have made a difference in the field I work for by consistently delivering outcomes that exceed the target expectations. If I were to provide a few instances, - Recruiting the first patient in the EEMEA area for the Kamilla MBC trial,- Increasing the target number of patients in Stevie Phase II BBC trial from 5 to 10, Kamilla Phase III MBC trial from 30 to 50, the Gen C HCV study from 200 to 300, making it the third country with the most patients among 30 countries, and increasing the target number of patients in the Pegbase study from 150 to 200, making it the fourth country with the most patients among 27 countries. - 2008, 2009, 2011 and 2014 performance evaluation results; “Exceeded Expectations”For more information please check my Linkedin profile.*****Feel free to connect with me here on Linkedin if you'd like to stay in touch.Contact > esma.ok79@gmail.com